RA Capital Management Overview
- Investor Type
-
Hedge Fund
- Status
-
Active
- Professionals
-
43

- Investments
-
385
- Portfolio
-
139
- Exits
-
180

RA Capital Management General Information
Description
Founded in 2001, RA Capital Management is a hedge fund manager based in Boston, Massachusetts. The firm employs a long/short and sector-oriented hedge fund strategy. Th firm also invests in early-stage companies. The firm prefers to invest in healthcare and life science companies developing drugs, medical devices, services & research tools, and diagnostics sectors based in the United States and Europe.
Contact Information
Website
www.racap.com
Year Founded
2001
Investor Status
Actively Seeking New Investments
Trade Association
New England Venture Capital Association (NEVCA)
Primary Investor Type
Hedge Fund
Other Investor Types
Growth/Expansion
Venture Capital
Primary Office
- 200 Berkeley Street
- 18th Floor
- Boston, MA 02116
- United States
+1 (617) 000-0000
RA Capital Management Investments & Acquisitions (385)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Pluton Biosciences | 02-Jun-2023 | Later Stage VC | 000.00 | Biotechnology | Generating Revenue | 0000000 000000000 00 |
000000 00000000000 | 25-May-2023 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - General | |
000000000 000 | 16-May-2023 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 2 | |
0000000000 0000000 | 27-Apr-2023 | 00000 00000 | 0000 | Biotechnology | Pre-Clinical Trials | 0000 000000 00.0 |
0000000 (000000000 | 17-Apr-2023 | 00000 00000 | 000.00 | Clinics/Outpatient Services | Generating Revenue | 000000 0000000000 |
0000000 0000000000 | 13-Apr-2023 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 1 | |
0000000 | 04-Apr-2023 | 00000 00000 | 000.00 | Drug Discovery | Pre-Clinical Trials | 0000 00000 00.0 |
00000000 000 | 04-Apr-2023 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000000 0000000 00.0 |
Orchard Therapeutics | 10-Mar-2023 | PIPE | 00000 | Drug Discovery | Generating Revenue | |
Unicycive | 08-Mar-2023 | PIPE | 00000 | Drug Discovery | Generating Revenue |
RA Capital Management Exits (180)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Mineralys | 10-Feb-2023 | IPO | 00000 |
0000000000 | 12-Dec-2022 | 000000000000000000 | |
0000000 0000000000 | 15-Nov-2022 | 000 | 000.00 |
000 00000000000000 | 08-Nov-2022 | 0000000 000000 | 00000 |
0000000 | 27-Sep-2022 | 000000000000000000 | 00000 |
00000 000000000000 | 01-Sep-2022 | 000000000000000000 | 00.00 |
00000 | 30-Jun-2022 | 000000 0000000000 | 000.00 |
00000000 000000000 | 16-Jun-2022 | 000000000 00000000 | |
PepGen | 06-May-2022 | IPO | 00000 |
HilleVax | 29-Apr-2022 | IPO | 00000 |
RA Capital Management Investments by Industry, Year, and Region
RA Capital Management Team (101)
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Gregg Rubin | Chief Credit Officer & President | Boston, MA | |||
Reza Halse Ph.D | President | 0 | 0 | 0 | Boston, MA |
Michael Saulnier | Chief Financial Officer | Boston, MA | |||
Andrew Levin Ph.D | Partner & Managing Director | 00 | 0 | 00 | Boston, MA |
Pieter Boelhouwer JD | Partner & Managing Director, Strategy & Operations | 0 | Boston, MA |
RA Capital Management Co-Investors (573)
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
Janus Henderson Investors | 32 | 0 | 0 |
![]() |
![]() |
Logos Capital | 00 | 0 | 00 |
![]() |
![]() |
OrbiMed | 00 | 0 | 00 |
![]() |
![]() |
Cormorant Asset Management | 00 | 0 | 0 |
![]() |
![]() |
Perceptive Advisors | 00 | 0 | 00 |
![]() |
![]() |